Preferred Label : Anti-PD-1/LAG-3 Bispecific Antibody AK129;
NCIt synonyms : PD-1 x LAG-3 Bispecific Antibody AK129;
NCIt definition : A humanized, immunoglobulin G1 (IgG1) bispecific antibody directed against the human
negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1;
PD1; PDCD1; CD279; programmed death 1) and lymphocyte activation gene 3 protein (LAG-3;
LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration, anti-PD-1/LAG-3 bispecific antibody AK129 targets and binds to
both PD-1 and LAG-3 expressed on T-cells, thereby blocking the interaction of PD-1
to its ligand programmed cell death-ligand 1 (PD-L1; cluster of differentiation 274;
CD274) and of LAG-3 to its ligand major histocompatibility complex II (MHCII). This
inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation
and abrogates downstream immune suppression. This may lead to a cytotoxic T-lymphocyte
(CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles
in suppressing T-cell activation and proliferation and promote tumor immune escape.;
Molecule name : AK-129; AK 129;
NCI Metathesaurus CUI : CL1906403;
Origin ID : C198979;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
